XenoPort CEO Ronald W. Barrett Acquires 2,600 Shares (XNPT)
XenoPort (NASDAQ:XNPT) CEO Ronald W. Barrett bought 2,600 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were purchased at an average price of $3.75 per share, for a total transaction of $9,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 173,458 shares in the company, valued at approximately $650,468. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
XenoPort (NASDAQ:XNPT) opened at 4.19 on Friday. XenoPort has a one year low of $3.15 and a one year high of $7.20. The stock has a 50-day moving average of $3.95 and a 200-day moving average of $5.25. The company’s market cap is $259.3 million.
XenoPort (NASDAQ:XNPT) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.04. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.86 million. During the same quarter in the previous year, the company posted ($0.50) earnings per share. The company’s revenue for the quarter was up 639.1% on a year-over-year basis. On average, analysts predict that XenoPort will post $-1.46 earnings per share for the current fiscal year.
XNPT has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of XenoPort in a research note on Thursday, May 15th. They now have a $6.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of XenoPort from $12.00 to $10.00 in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $6.22.
XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.